Catalog No.
PHG32201
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human FAP (Ile523-Asp760).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Surface-expressed protease,Gelatine degradation protease FAP,Integral membrane serine protease,Dipeptidyl peptidase FAP,Seprase,FAP,Post-proline cleaving enzyme,APCE,SIMP,FAPalpha,170 kDa melanoma membrane-bound gelatinase,Fibroblast activation protein alpha,Serine integral membrane protease,Prolyl endopeptidase FAP
Purification
Purified by antigen affinity column.
Accession
Q12884
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fibroblast Activation Protein as a Molecular Handle in Cancer Phototheranostics: Recent Advances., PMID:40457867
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma., PMID:40406146
Preclinical Evaluation of a Nanobody-based SPECT Radiotracer 99mTc-AFN with Clinical Potential for Noninvasive Monitoring of Fibroblast Activation after Myocardial Infarction., PMID:40402089
Treatment of Pancreatic Cancer Using Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Combination with Anticancer Chemotherapeutic Drug., PMID:40361512
[A Case of Rectal Cancer with Lateral Lymph Node, Liver and Lung Metastases after Surgery, Successfully Undergoing Radical Resection with Multidisciplinary Treatment]., PMID:40360412
An anti-FAP-scFv-functionalized exosome-carrying hydrogel delivers SKI mRNA to fibrotic nucleus pulposus cells to alleviate intervertebral disc degeneration by regulating FOXO3., PMID:40213661
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity., PMID:40111090
Novel Clinical PET Tracers in the Pipeline for Melanoma., PMID:40072700
Periarticular myositis and muscle fibrosis are cytokine-dependent complications of inflammatory arthritis., PMID:40036069
Cryo-electron microscopy reveals a single domain antibody with a unique binding epitope on fibroblast activation protein alpha., PMID:39975582
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models., PMID:39933836
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma., PMID:39895413
Radiotheranostic landscape: A review of clinical and preclinical development., PMID:39891713
Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library., PMID:39868181
Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study., PMID:39863371
FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity., PMID:39828123
FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy., PMID:39800373
FAP-targeting biomimetic nanosystem to restore the activated cancer-associated fibroblasts to quiescent state for breast cancer radiotherapy., PMID:39788396
Interleukin-1β Drives Disease Progression in Arrhythmogenic Cardiomyopathy., PMID:39763850
Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule-Drug Conjugates Elicits Potent In Vivo Anticancer Activity., PMID:39718420
Glycosylation-Targeting Aptamer for the Feasible Construction of a Dual Aptamer-Based Plasmonic Immunosandwich Assay in Cancer Diagnostics., PMID:39710916
[Patterns of CAF expression in tumors of the genitourinary system]., PMID:39686894
[Localization features of FAP-positive activated stromal cells in fibrosis in patients with new coronavirus infection COVID-19]., PMID:39686891
A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts., PMID:39629565
Comparison of [18F]FAPI-42 and [18F]FDG PET/CT in the evaluation of systemic vasculitis., PMID:39601894
Surveillance of SARS-CoV-2 in Healthcare Workers Before and After COVID-19 Vaccination: A Cohort Study in a Primary Care Unit of Brazil., PMID:39595495
Immunohistochemical Localization of Fibroblast Activation Protein in Coronary Arteries with Different Forms of Atherosclerosis., PMID:39590809
FAP-α is an effective tool to evaluate stroma invasion of lung adenocarcinoma., PMID:39587644
Immuno-PET Imaging of CD93 Expression with 64Cu-Radiolabeled NOTA-mCD93 ([64Cu]Cu-NOTA-mCD93) and Insulin-Like Growth Factor Binding Protein 7 ([64Cu]Cu-NOTA-IGFBP7)., PMID:39533706
Development of cancer-associated fibroblasts-targeting polymeric nanoparticles loaded with 8-O-methylfusarubin for breast cancer treatment., PMID:39507587
Cryo-electron microscopy reveals a single domain antibody with a unique binding epitope on fibroblast activation protein alpha., PMID:39463996
Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL., PMID:39444607
Targeting immune-fibroblast cell communication in heart failure., PMID:39443792
Sensitive quantification of fibroblast activation protein and high-throughput screening for inhibition by FDA-approved compounds., PMID:39437576
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma., PMID:39422604
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma., PMID:39395231
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease., PMID:39362770
Utilizing MRI, [18F]FDG-PET and [89Zr]Zr-DFO-28H1 FAP-PET tracer to assess inflammation and fibrogenesis in a reproducible lung injury rat model: a multimodal imaging study., PMID:39355041
Activation of fibroblasts by plasma cells via PDGF/PDGFR signaling in IgG4-related sialadenitis., PMID:39343610
Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers., PMID:39335130
[18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial., PMID:39327020
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting., PMID:39266288
Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model., PMID:39237746
Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent., PMID:39159402
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors., PMID:39140264
Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway., PMID:39137851
Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer., PMID:39048805
Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice., PMID:39008063
UniCAR T-Cell Potency-A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?, PMID:39000348
[The immunocytokine FAP-IL2v : a potent co-therapy for preventing resistance to trastuzumab in HER2+ breast cancer]., PMID:38986105
For research use only. Not for human or drug use.
